ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 186 DKK 0.22% Market Closed
Market Cap: 37.7B DKK

Relative Value

The Relative Value of one ALK B stock under the Base Case scenario is 227.82 DKK. Compared to the current market price of 186 DKK, ALK-Abello A/S is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALK B Relative Value
Base Case
227.82 DKK
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
30
vs Industry
23
Median 3Y
6
Median 5Y
6.5
Industry
2.7
Forward
6.5
vs History
77
vs Industry
11
Median 3Y
49.5
Median 5Y
57.1
Industry
22.2
Forward
36.5
vs History
79
vs Industry
16
Median 3Y
37.9
Median 5Y
46.5
Industry
17.2
vs History
26
vs Industry
3
Median 3Y
96.9
Median 5Y
81.8
Industry
23.7
vs History
39
vs Industry
12
Median 3Y
6.3
Median 5Y
6.8
Industry
2.3
vs History
33
vs Industry
22
Median 3Y
6
Median 5Y
6.5
Industry
2.8
Forward
6.5
vs History
36
vs Industry
24
Median 3Y
9.5
Median 5Y
10.2
Industry
5.6
vs History
60
vs Industry
16
Median 3Y
27.3
Median 5Y
29.4
Industry
13.3
Forward
21.3
vs History
73
vs Industry
16
Median 3Y
36.3
Median 5Y
40.4
Industry
16.5
Forward
25.8
vs History
79
vs Industry
17
Median 3Y
38.8
Median 5Y
47
Industry
15.6
vs History
3
vs Industry
6
Median 3Y
173.6
Median 5Y
174.1
Industry
17.9
vs History
30
vs Industry
18
Median 3Y
4.5
Median 5Y
4.8
Industry
2

Multiples Across Competitors

ALK B Competitors Multiples
ALK-Abello A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
ALK-Abello A/S
CSE:ALK B
41.2B DKK 7.2 44 27 33.1
US
Eli Lilly and Co
NYSE:LLY
661.8B USD 12.4 48 28.5 30.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
429.5B USD 4.7 19 14.4 19
CH
Roche Holding AG
SIX:ROG
208.7B CHF 3.5 25.2 9.5 11.1
UK
AstraZeneca PLC
LSE:AZN
185.7B GBP 4.4 30.2 113.6 169.9
CH
Novartis AG
SIX:NOVN
198.2B CHF 4.5 18 10.8 14.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.9 13.8 10.1 11.2
US
Merck & Co Inc
NYSE:MRK
213.3B USD 3.4 13 8.3 10
IE
Endo International PLC
LSE:0Y5F
183.4B USD 79.1 -62.7 291.8 731.8
US
Pfizer Inc
NYSE:PFE
144.7B USD 2.3 13.5 7.6 10.4
P/E Multiple
Earnings Growth PEG
DK
ALK-Abello A/S
CSE:ALK B
Average P/E: 25
44
23%
1.9
US
Eli Lilly and Co
NYSE:LLY
48
49%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19
27%
0.7
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
30.2
36%
0.8
CH
Novartis AG
SIX:NOVN
18
16%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
13.8
18%
0.8
US
Merck & Co Inc
NYSE:MRK
13
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.7 N/A N/A
US
Pfizer Inc
NYSE:PFE
13.5
30%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBITDA: 397.1
27
21%
1.3
US
Eli Lilly and Co
NYSE:LLY
28.5
30%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.4
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
113.6
10%
11.4
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
DK
Novo Nordisk A/S
CSE:NOVO B
10.1
13%
0.8
US
Merck & Co Inc
NYSE:MRK
8.3
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
291.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBIT: 1 704
33.1
23%
1.4
US
Eli Lilly and Co
NYSE:LLY
30.9
33%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
19
14%
1.4
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
169.9
23%
7.4
CH
Novartis AG
SIX:NOVN
14.3
10%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
731.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
9%
1.2